comparisonApril 25, 2026·7 min read

PT-141 vs Melanotan 2: Key Differences

PT-141 is FDA-approved for sexual function, MT-2 is not — but MT-2 adds tanning. Side-by-side on effects, safety, and cost.

Save

PT-141 vs Melanotan 2: Key Differences

PT-141 (bremelanotide) was literally born from Melanotan-2. When researchers discovered that MT-2 caused powerful sexual arousal as a "side effect" during tanning studies, they engineered a modified version to target sexual function specifically — that became PT-141 (Hadley & Dorr, 2006).

Despite sharing a molecular ancestor, these two peptides serve fundamentally different purposes. This guide breaks down exactly where they overlap, where they diverge, and which one fits your goals.

Side-by-side evidence

Outcomes where both peptides have published data. Each cell carries two grades: clinical evidence (human-RCT depth for this specific outcome) and community evidence (real-world adoption). How we grade evidence.

OutcomeMelanotan IIPT-141
Sexual arousal / libido
Clinical:Weak
Community:Strong

Strong libido and erectogenic effects reported by users; not FDA-approved.

Clinical:Strong
Community:Moderate

FDA-approved (bremelanotide) for HSDD in premenopausal women.

Tanning effect
Clinical:Weak
Community:Strong

Reliably increases melanogenesis — primary draw for many users.

Clinical:Preliminary
Community:Moderate

Minimal tanning effect; metabolite lacks MT-2's MC1R activity.

Side effect burden
Clinical:Weak
Community:Strong

Nausea, BP changes, mole darkening, and rare melanoma reports — meaningful safety concerns.

Clinical:Moderate
Community:Moderate

Nausea (~40%), flushing, transient BP rise; cleaner safety profile than MT-2.

Quick Comparison

Feature PT-141 (Bremelanotide) Melanotan-2
Primary use Sexual function (desire + arousal) Tanning (with sexual side effects)
FDA status ✅ Approved (HSDD in women) ❌ Not approved for any indication
Receptor targets MC3R, MC4R (brain) MC1R, MC3R, MC4R, MC5R (body-wide)
Tanning effect Minimal to none Significant
Sexual enhancement Strong, targeted Strong, but untargeted
Typical dose 500 mcg–1 mg (as needed) 250–500 mcg (daily during loading)
Dosing pattern On-demand before activity Daily loading → weekly maintenance
Nausea severity Moderate (40%) Severe during loading (80-90%)
Mole/skin changes No Yes — requires monitoring
Appetite effects Minimal Significant suppression

The Origin Story: How PT-141 Came From MT-2

Understanding the relationship between these peptides explains their differences:

1990s: Researchers at the University of Arizona developed MT-2 as a tanning agent. During Phase I trials, male subjects unexpectedly reported spontaneous erections (Dorr et al., 1996).

1998: Wessells et al. confirmed MT-2's erectogenic properties in a double-blind trial — 8 of 10 men with psychogenic ED developed clinically apparent erections (Wessells et al., 1998).

2000s: Palatin Technologies modified MT-2's structure to create bremelanotide (PT-141), retaining MC3R/MC4R selectivity for sexual function while reducing MC1R activity (tanning) and improving the pharmacological profile.

2019: PT-141 received FDA approval (as bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women, following successful RECONNECT Phase III trials (Kingsberg et al., 2019).

MT-2 never progressed past Phase I for tanning. Its sexual effects remained a "side effect" rather than a feature.

Mechanism of Action: Same Family, Different Targets

Both peptides work through the melanocortin receptor system, but their selectivity profiles are dramatically different.

PT-141: Precision Targeting

PT-141 primarily activates MC3R and MC4R in the hypothalamus — the brain region controlling sexual desire and arousal. This triggers:

  • Dopamine release in reward/motivation circuits
  • Enhanced neural signaling for sexual desire
  • Increased genital arousal through central (not peripheral) mechanisms

This is fundamentally different from PDE5 inhibitors (Viagra, Cialis) which work on blood vessels. PT-141 makes you want sex; PDE5 inhibitors help the mechanics. They can even be combined.

Melanotan-2: Broad Activation

Receptor Selectivity Comparison

MT-2 activates all five melanocortin receptor subtypes:

  • MC1R → Melanin production (tanning)
  • MC3R → Energy homeostasis, sexual arousal
  • MC4R → Appetite regulation, sexual function, erectile response
  • MC5R → Sebaceous gland function

This non-selective binding is why MT-2 produces tanning AND sexual effects AND appetite suppression AND nausea — it's hitting every melanocortin pathway at once.

Sexual Function: Head-to-Head

Both peptides enhance sexual function, but through different approaches:

Desire & Arousal

Metric PT-141 MT-2
Onset of sexual effects 15-30 minutes 1-4 hours
Duration 4-6 hours Variable (may persist)
Effect on desire Strong, consistent Strong but unpredictable
Effect on arousal Central + some genital Central + genital
Clinical evidence Phase III (1,267 women) Phase I only
Works for women Yes (FDA-approved) Anecdotal reports

For Erectile Dysfunction

PT-141 is the clear winner for ED:

  • Purpose-built for the indication
  • Works via central arousal (complements PDE5 inhibitors)
  • On-demand dosing matches sexual activity timing
  • Clinical data in men with psychogenic ED

MT-2 can help ED as a side effect, but:

  • Requires daily dosing during loading (not on-demand)
  • ED benefits come bundled with tanning, nausea, appetite loss
  • No dose optimization for sexual function specifically
  • Sexual effects are less predictable in timing

Ready to buy? Compare verified vendors on our best PT-141 sources page, or browse all coupon codes for up to 50% off.

CategorySexual Health & Hormone Peptides
Classmelanocortin agonist
GoalSexual Health
Best Kit Deal10-VialCOASave 55%

Ascension Peptides — 10mg × 10 (100mg) — $387 $194 (50% off) ($1.94/mg)

Top PT-141 Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptidePREMIUMCOA
10/10
10mg$4.00/mg
2
Ascension PeptidesCOA
9.8/10
10mg$4.90/mg
3
Ion PeptideCOA
9.5/10
10mg$3.70/mg
See full vendor rankings for PT-141 →

Top Melanotan II Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptidePREMIUMCOA
10/10
10mg$4.00/mg
2
Ascension PeptidesCOA
9.8/10
10mg$4.30/mg
3
Ion PeptideCOA
9.6/10
$3.50/mg
See full vendor rankings for Melanotan II →

Tanning: No Contest

PT-141 does not produce meaningful tanning. Its reduced MC1R affinity means melanocyte stimulation is minimal. If tanning is your goal, PT-141 is the wrong peptide entirely.

MT-2 produces significant tanning through MC1R activation:

  • Visible results in 1-2 weeks of loading
  • Deep tan even with minimal UV exposure
  • Requires maintenance dosing to sustain

If you want both tanning and sexual function, MT-2 delivers both. If you want only sexual function, PT-141 is cleaner and safer.

Side Effect Comparison

This is where the two peptides diverge most dramatically:

Side Effect PT-141 MT-2
Nausea 40% (usually mild) 80-90% during loading (can be severe)
Facial flushing Common, brief Common, more intense
Appetite suppression Minimal Significant (MC4R-mediated)
Mole changes No Yes — requires dermatological monitoring
Melanoma concern No Theoretical risk (case reports exist)
Spontaneous erections Possible More common, higher doses
Fatigue Mild Moderate during loading
Injection site darkening No Yes

For a deep dive on every MT-2 side effect with management protocols, see our MT-2 Side Effects Guide.

Safety & Regulatory Status

PT-141: FDA-Approved

PT-141 (bremelanotide) completed the full FDA approval pathway:

  • Two Phase III trials (RECONNECT) with 1,267 women
  • Established safety profile over 24-week treatment periods
  • Known drug interactions (minimal — low CYP enzyme metabolism)
  • Maximum frequency: one dose per 24 hours

MT-2: Unregulated

MT-2 has only completed Phase I clinical trials (safety/tolerability in small groups):

  • No Phase II or III efficacy/safety data for tanning
  • All available product is unregulated research chemical
  • No standardized manufacturing or quality control
  • Purity varies significantly between sources

This regulatory gap is the single biggest difference in risk profile between these peptides.

Dosing Comparison

Parameter PT-141 MT-2
Starting dose 500 mcg 100-250 mcg
Standard dose 500 mcg–1 mg 250-500 mcg
Frequency As needed (max 1x/24h) Daily (loading) → 1-2x/week (maintenance)
Route Subcutaneous Subcutaneous
Timing 30 min before activity Before bed (to sleep through nausea)
Loading required No Yes (2-3 weeks)
Vial size 10 mg typical 10 mg typical

PT-141's on-demand dosing is a significant practical advantage — you use it only when you need it, rather than committing to a daily loading protocol.

For detailed protocols, see our PT-141 Dosing Guide and MT-2 Dosing Guide.

Which Should You Choose?

PT-141 vs MT-2 Decision Guide

Choose PT-141 if:

  • Sexual function is your only goal — desire, arousal, or ED
  • Safety matters — you want an FDA-approved, clinically tested peptide
  • You want on-demand use — take it only when needed
  • You don't want tanning — PT-141 won't change your skin color
  • Nausea is a concern — PT-141's nausea profile is significantly milder
  • You have mole concerns — PT-141 doesn't affect melanocytes

Choose MT-2 if:

  • You want tanning as the primary goal — with sexual effects as a bonus
  • You want both tanning AND sexual enhancement — MT-2 delivers both
  • Cost is a priority — MT-2 is generally cheaper per vial
  • You're comfortable with unregulated products — and accept the additional risk
  • You've had a dermatological baseline — and will monitor moles regularly

Consider Neither if:

  • You have melanoma history — avoid MT-2; PT-141 is fine but won't help tanning
  • You're on blood pressure medication — consult your physician first
  • You want only tanning without sexual effects — consider Melanotan-1 instead

Frequently Asked Questions

What is the difference between PT-141 and Melanotan 2?
PT-141 (bremelanotide) is a modified fragment of Melanotan-2 designed specifically for sexual function. PT-141 primarily targets MC3R/MC4R in the brain for arousal and desire, with minimal tanning. MT-2 hits all five melanocortin receptors, producing significant tanning plus sexual side effects, appetite suppression, and nausea.
Can PT-141 be used for tanning?
No — PT-141 has minimal MC1R activity and does not produce meaningful tanning. It was specifically engineered from MT-2 to isolate the sexual function effects while removing the tanning component. Use Melanotan-2 or Melanotan-1 for tanning.
Is PT-141 safer than Melanotan 2?
Yes, by a significant margin. PT-141 is FDA-approved (for HSDD in premenopausal women) with extensive Phase III safety data. MT-2 has only completed Phase I trials and carries additional risks from non-selective receptor binding, including mole changes, appetite disruption, and more severe nausea.
What do community sources describe about combining PT-141 and Melanotan 2?
This is generally not recommended. Both activate MC3R/MC4R, so combining them provides redundant receptor stimulation with additive side effects (especially nausea). If you want tanning plus sexual enhancement, MT-2 alone provides both. If you want sexual function only, PT-141 alone is cleaner.
Which is better for erectile dysfunction — PT-141 or Melanotan 2?
PT-141 is the better choice for ED. It's designed specifically for sexual function, has FDA clinical data, uses lower doses, has fewer side effects, and works on-demand. MT-2 was never optimized for ED — its sexual effects are a side effect of tanning protocols.
How much cheaper is Melanotan 2 vs PT-141?
MT-2 is typically 30-50% cheaper per vial, but the per-use cost comparison depends on dosing. MT-2 at 250-500 mcg daily for tanning costs less per dose than PT-141 at 500 mcg-1 mg on-demand. However, MT-2 requires daily loading while PT-141 is used only when needed.

References

Citation Topic PMID
Hadley & Dorr, Peptides (2006) Melanocortin peptide therapeutics, MT-I/PT-141 development 16412534
Dorr et al., Life Sci (1996) MT-II Phase I trial, erectogenic discovery 8637402
Wessells et al., J Urol (1998) MT-II double-blind ED trial, 8/10 responders 9679884
Kingsberg et al., Obstet Gynecol (2019) RECONNECT Phase III, bremelanotide for HSDD 31599840
Van der Ploeg et al., PNAS (2002) MC4R role in sexual function and erectile modulation 12172010

For educational and research purposes only. This is not medical advice. PT-141 is FDA-approved for specific indications; Melanotan-2 is not approved for any indication. Consult a healthcare provider.